Status:
COMPLETED
Efficacy and Safety of a Sore Throat Lozenge Containing Lidocaine and Cetylpyridinium Chloride in Patients With Sore Throat Due to a Common Cold.
Lead Sponsor:
Novartis
Conditions:
Sore Throat Due to a Common Cold
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will compare the efficacy and safety of a single dose of a lidocaine 8 mg + cetylpyridimium chloride (CPC) 2 mg lozenge with a single dose of a lidocaine 1 mg + CPC 2 mg lozenge in the trea...
Eligibility Criteria
Inclusion
- Patients with sore throat due to an upper respiratory tract infection, with recent onset (within 48 hours)
- Sore throat of at least moderate pain intensity
Exclusion
- \- History of hypersensitivity to any of the study drugs and listed excipients or to drugs of similar chemical classes
- Evidence of mouth breathing or severe coughing
- Evidence of overt oropharyngeal bacterial or fungal infection or evidence of lower respirator tract infection
- Severe renal, liver or cardiac impairment
- Severe lung disease
Key Trial Info
Start Date :
December 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2011
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT01265446
Start Date
December 1 2010
End Date
April 1 2011
Last Update
April 24 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Socratec
Erfurt, Germany